In an interview conducted during the 47th Annual Meeting of the European Group for Blood and Marrow Transplantation (EBMT) in 2021, Nikhil Munshi, MD, Director of Basic and Correlative Science, Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, and Professor of Medicine, Boston, MA, discusses how the COVID-19 pandemic has affected the treatment and management of multiple myeloma. Results from an analysis of 650 patients who were hospitalized with COVID-19 demonstrated that age, renal disease, high-risk status, and suboptimal control of multiple myeloma were predictive of adverse outcomes. Dr Munshi also discusses recommendations for COVID-19 vaccination for patients with multiple myeloma.